Editas Medicine (NASDAQ:EDIT) has seen a positive shift in analyst ratings over the last three months, with an average 12-month price target now at $14.00, up 27.27% from $11.00. Analysts from Citigroup, Barclays, JP Morgan, and Truist Securities have all raised their price targets, reflecting optimism about the company's future performance. Editas Medicine, a genome editing company, has shown remarkable financial health with a revenue growth rate of 12604.76% as of September 30, 2023, and strong market capitalization, net margin, ROE, and ROA figures.